Intl. Filing Date: 1 July 2004

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original). A compound of formula (I),

(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R and \mathbf{R}^0 are each independently hydrogen, halogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, aryl, cyano and, when R and R⁰ are on adjacent carbon atoms, methylenedioxy and ethylenedioxy;

 $\mathbf{R^1}$ is hydrogen, $C_{1\text{-}6}$ alkyl, $C_{3\text{-}6}$ alkenyl, $C_{3\text{-}6}$ alkinyl, aryl $C_{1\text{-}6}$ alkyl, heteroaryl $C_{1\text{-}6}$ alkyl, $(C_{3\text{-}7}$ cycloalkyl)alkyl, amino $C_{1\text{-}6}$ alkyl, $(C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, hydroxy $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkoxy $C_{1\text{-}6}$ alkyl, aryloxy $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl, where each aryl or heteroaryl can be substituted one or more times by halogen, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkyl, hydroxy, amino, $C_{1\text{-}6}$ alkylamino, di($C_{1\text{-}6}$ alkyl)amino, amino $C_{1\text{-}6}$ alkyl, ($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, di($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, aryl or perhalo $C_{1\text{-}6}$ alkyl;

 \mathbf{R}^2 is $C_{3\text{-}7}$ cycloalkyl, aryl, heteroaryl, aryl $C_{1\text{-}6}$ alkyl, heteroaryl $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl, hydroxy $C_{1\text{-}6}$ alkyl, aminocarbonyl, $C_{1\text{-}6}$ alkylaminocarbonyl, di($C_{1\text{-}6}$ alkyl)aminocarbonyl where each aryl or heteroaryl can be substituted one or more times by halogen, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkyl, hydroxy, amino, $C_{1\text{-}6}$ alkylamino, di($C_{1\text{-}6}$ alkyl)amino, amino $C_{1\text{-}6}$ alkyl, ($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, aryl or perhalo $C_{1\text{-}6}$ alkyl;

Intl. Filing Date: 1 July 2004

Q is a moiety of formula:

$$\mathbb{R}^5$$

wherein:

 $\mathbf{R^3}$ and $\mathbf{R^4}$ are each independently hydrogen, halogen, $C_{1\text{-}6}$ alkyl, perhalo $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkoxy, hydroxy, amino, $C_{1\text{-}6}$ alkylamino, di($C_{1\text{-}6}$ alkyl)amino, amino $C_{1\text{-}6}$ alkyl, ($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, aryl;

R⁵ is hydrogen or C₁₋₆alkyl, and

R⁶ is hydrogen or hydroxymethyl.

- 2. (Original). A compound of formula (I) according to claim 1, wherein R and R^0 independently represent hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy.
- 3. (Original). A compound of formula (I) according to claim 2, wherein R and R⁰ independently represent hydrogen, chlorine, fluorine, methyl, methoxy.
- 4. (Currently Amended). A compound of formula (I) according to any one of claims 1-3 claim 1, wherein R^1 is hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkinyl, aryl C_{1-6} alkyl, (C_{3-7} cycloalkyl)alkyl, hydroxy C_{1-6} alkyl, CO-aryl, SO₂-aryl.
- 5. (Original). A compound of formula (I) according to claim 4, wherein R¹ is hydrogen, methyl, n-propyl, isopentyl, allyl, 2-hydroxyethyl, cyclopropylmethyl, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, bromobenzyl, methoxybenzyl, methylbenzyl, *t*-butylbenzyl, trifluoromethylbenzyl, diphenylmethyl, phenoxyethyl, 2-naphthylmethyl, benzoyl, benzenesulfonyl.
- 6. (Currently Amended). A compound of formula (I) according to any one of claims 1-6 claim 1, wherein R^2 is aryl, heteroaryl, aryl C_{1-6} alkyl, C_{1-6} alkoxycarbonyl.

Intl. Filing Date: 1 July 2004

7. (Original). A compound of formula (I) according to claim 6, wherein R² is phenyl, chlorophenyl, methoxyphenyl, fluorophenyl, 2-furyl, 2-thienyl, 2-pyridyl, benzyl, ethoxycarbonyl.

- 8. (Currently Amended). A compound of formula (I) according to any one of claims 1-7 claim 1, wherein R^3 and R^4 independently represent hydrogen, halogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{1-6} alkoxy.
- 9. (Original). A compound of formula (I) according to claim 8, wherein R³ and R⁴ independently represent hydrogen, chlorine, fluorine, bromine, methyl, methoxy, trifluoromethyl.
- 10. (Currently Amended). A compound of formula (I) according to claims 1-9, wherein R⁵ and R⁶ represent hydrogen.
- 11. (Original). A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from:
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-methyl-1H-indole;
- 2-(4-Chloro-phenyl)-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-Phenyl-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 2-Phenyl-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 2-(2-Chloro-phenyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(2-Chloro-phenyl)-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(2-Chloro-phenyl)-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(2-Chloro-phenyl)-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;

- Intl. Application No.: PCT/EP2004/007294
- Intl. Filing Date: 1 July 2004
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-(2-methoxy-phenyl)-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-(2-methoxy-phenyl)-1H-indole;
- 2-(2-Methoxy-phenyl)-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(2-Methoxy-phenyl)-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-(3-methoxy-phenyl)-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-(3-methoxy-phenyl)-1H-indole;
- 2-(3-Methoxy-phenyl)-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(3-Methoxy-phenyl)-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 2-(4-Chloro-phenyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(4-Chloro-phenyl)-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(4-Chloro-phenyl)-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-(4-fluoro-phenyl)-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-(4-fluoro-phenyl)-1H-indole;
- 2-(4-Fluoro-phenyl)-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-(4-Fluoro-phenyl)-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-furan-2-yl-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-furan-2-yl-1H-indole;
- 2-Furan-2-yl-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-Furan-2-yl-3-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-pyridin-2-yl-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-pyridin-2-yl-1H-indole;
- 2-Pyridin-2-yl-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 3-(4-Phenyl-piperidin-1-ylmethyl)-2-pyridin-2-yl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-thiophen-2-yl-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-thiophen-2-yl-1H-indole;

Intl. Filing Date: 1 July 2004

2-Thiophen-2-yl-3-[4-(2-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;

3-(4-Phenyl-piperidin-1-ylmethyl)-2-thiophen-2-yl-1H-indole;

2-Benzyl-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;

2-Benzyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;

3-[4-(4-Methoxy-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2-Fluoro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(3-Fluoro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(4-Fluoro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

2-Phenyl-3-[4-(4-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;

3-[4-(2-Chloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(3-Chloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(4-Chloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

2-Phenyl-3-(4-o-tolyl-piperidin-1-ylmethyl)-1H-indole;

3-[4-(2-Bromo-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2,3-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2,5-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2,6-Difluoro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(3-Bromo-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2-Methoxy-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-phenyl-1H-indole;

3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;

3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-methyl-1H-indole;

Cis-[4-Phenyl-1-(2-phenyl-1H-indol-3-ylmethyl)-piperidin-3-yl]-methanol;

Trans-[4-Phenyl-1-(2-phenyl-1H-indol-3-ylmethyl)-piperidin-3-yl]-methanol;

5-Chloro-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-methoxy-2-phenyl-1H-indole;

7-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-6-phenyl-5H-[1,3]dioxolo[4,5-f]indole;

3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-1-(2-hydroxy-ethyl)-2-phenyl-1H-indol-5-ol;

7-Bromo-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-2-methyl-1H-indole;

- Intl. Application No.: PCT/EP2004/007294
- Intl. Filing Date: 1 July 2004
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-methyl-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole-2-carboxylic acid ethyl ester;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole-6-carbonitrile;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-1,2-diphenyl-1H-indole;
- 3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid amide trifluoroacetate;
- 3-{1-[4-(2,6-Dimethyl-phenyl)-piperidin-1-yl]-ethyl}-1H-indole;
- {3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indol-2-yl}-methanol;
- 1-Benzyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1-propyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-methyl-2-phenyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-phenyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-methyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 1-Benzyl-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-2-methyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 1-Benzyl-5-chloro-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 1-Benzyl-3-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-5-methoxy-2-phenyl-1H-indole;
- 5-Benzyl-7-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-6-phenyl-5H-[1,3]dioxolo[4,5-f]indole;
- {3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-phenyl-indol-1-yl}-acetic acid methyl ester;
- 3-(4-(2,6-Dichloro-phenyl)piperidin-1-ylmethyl)-1-(2-hydroxyethyl)-2-phenyl-1H-indole;
- 2-{3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-phenyl-indol-1-yl}-ethanol;
- 2-{3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-indol-1-yl}-ethanol;
- 2-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-indol-1-yl}-ethanol;
- 2-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-methyl-indol-1-yl}-ethanol;

- Intl. Application No.: PCT/EP2004/007294
- Intl. Filing Date: 1 July 2004
- 2-{3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-methyl-indol-1-yl}-ethanol;
- 2-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-indol-1-yl}-ethanol;
- 3-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-2-phenyl-indol-1-yl}-propan-1-ol;
- 2-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-methoxy-2-phenyl-indol-1-yl}-ethanol;
- 2-{5-Chloro-3-[4-(2,6-dimethyl-phe nyl)-piperidin-1-ylmethyl]-2-phenyl-indol-1-yl}-ethanol;
- 2-{7-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-6-phenyl-[1,3]dioxolo[4,5-f]indol-5-yl}-ethanol;
- 2-{3-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-5-fluoro-2-methyl-indol-1-yl}-ethanol;
- 1-(4-*tert*-Butyl-benzyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(3-methyl-butyl)-2-phenyl-1H-indole;
- 1-Cyclopropylmethyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(3-methoxy-benzyl)-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(2-methyl-benzyl)-2-phenyl-1H-indole;
- 1-Cyclohexylmethyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(4-methyl-benzyl)-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(4-fluoro-benzyl)-2-phenyl-1H-indole;
- 1-(3-Chloro-benzyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;
- 1-(2-Chloro-benzyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;

Intl. Filing Date: 1 July 2004

- 1-(4-Chloro-benzyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 1-Allyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1-prop-2-ynyl-1H-indole;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(2-methoxy-benzyl)-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(4-methoxy-benzyl)-2-phenyl-1H-indole trifluoroacetate;
- 1-(4-Bromo-benzyl)-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;
- 1-Biphenyl-4-ylmethyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-naphthalen-2-ylmethyl-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(2-phenoxy-ethyl)-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(3-methyl-benzyl)-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(2-fluoro-benzyl)-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-(3-fluoro-benzyl)-2-phenyl-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1-(2-trifluoromethylbenzyl)-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1-(3-trifluoromethylbenzyl)-1H-indole trifluoroacetate;
- 3-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1-(4-trifluoromethylbenzyl)-1H-indole trifluoroacetate;
- 1-Benzenesulfonyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;
- 1-Benzoyl-3-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-2-phenyl-1H-indole trifluoroacetate;

Intl. Filing Date: 1 July 2004

- 2-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-3-methyl-1H-indole;
- 2-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-3-phenyl-1H-indole;
- 2-[4-(2-Chloro-6-fluoro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-3-methyl-1H-indole;
- 3-Methyl-2-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-Phenyl-2-(4-phenyl-piperidin-1-ylmethyl)-1H-indole;
- 3-Phenyl-2-(4-(3-trifluoromethylphenyl)piperidin-1-ylmethyl)-1H-indole;
- 2-[4-(2,6-Dimethyl-phenyl)-piperidin-1-ylmethyl]-3-phenyl-1H-indole;
- 2-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole;
- 2-[4-(2-Trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(3-Trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(4-Trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(3-Fluoro-2-methyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 5,6-Dichloro-2-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 5,6-Dichloro-2-[4-(2,6-dimethyl-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 1-Benzyl-2-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole;
- 2-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-propyl-1H-indole;
- 2-[4-(2,6-Dichloro-phenyl)-piperidin-1-ylmethyl]-1-methyl-1H-indole;
- 2-(4-(2,6-Dichlorophenyl)-piperidin-1-ylmethyl)-1-(2-hydroxyethyl)-1H-indole;
- 1-Benzoyl-2-[4-(2,6-dichloro-phenyl)-piperidin-1-ylmethyl]-1H-indole.
- 12. (Currently Amended). An enantiomer of a compound of formula (I) as described in any one of claims 1-11 claim 1.
- 13. (Currently Amended). A mixture of enantiomers of a compound of formula (I) as described in claims 1–11, where an enantiomer is present in greater proportion than its antipod.
- 14. (Currently Amended). A compound of formula (I) as defined in claims 1-13, for use as active therapeutic substance.

Intl. Filing Date: 1 July 2004

15. (Currently Amended). A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1-13 claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier therefore.

16. (Currently Amended). A process for preparing a compound of formula (I) as defined in claims 1-13, comprising the step of reacting a compound of formula (III)

$$\begin{array}{c}
R^6 \\
NH
\end{array}$$
(III)

wherein R^3 , R^4 , R^6 are as defined as in formula (I) of claim 1, with a compound of formula (VII),

wherein R, R⁰, R¹, R², are as defined as in formula (I) of claim 1 and W is hydrogen or a group capable of binding to the piperidinic nitrogen of said compound of formula (III).

17. (Original). A process according to claim 16 wherein the reaction between (VII) and (III) is a Mannich reaction, taking place in an organic solvent environment, in presence of a suitable aldehydic reagent and acetic acid.

18. (Original). A process according to claim 16, wherein W is formyl, acyl or carboxyl, and the compound resulting from the reaction of (VII) with (III) is

Intl. Filing Date: 1 July 2004

further treated with a reducing agent, thus obtaining said compound of formula (I), or the reaction of (VII) with (III) is a performed under reductive amination conditions, leading directly to said compound of formula (I).

19. (Original). A process according to claim 16, wherein R¹ in formula (VII) is hydrogen, further comprising the step of treating said compound (VII) or a derivative thereof, with a reagent of formula R¹-X where R¹ is defined as in claim 1 and X is a suitable leaving group.

20. (Original). A process according to claim 19, where said reaction with R¹-X takes place in basic conditions, or under phase transfer conditions.

21. (Original). Use of a compound of formula (VI)

(VI)

wherein:

R and R^0 are each independently hydrogen, halogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl)amino C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, aryl, cyano and, when R and R^0 are on adjacent carbon atoms, methylenedioxy and ethylenedioxy;

 R^1 is hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkinyl, $arylC_{1-6}$ alkyl, heteroaryl C_{1-6} alkyl, $(C_{3-7}$ cycloalkyl)alkyl, amino C_{1-6} alkyl, $(C_{1-6}$ alkyl)amino C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, aryloxy C_{1-6} alkyl, C_{1-6} alkyl, C_{1-6} alkyl, where each aryl or heteroaryl can be substituted one or more times by halogen, C_{1-6} alkoxy, C_{1-6} alkyl, hydroxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, amino C_{1-6} alkyl, (C_{1-6} alkyl).

Intl. Filing Date: 1 July 2004

6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or perhaloC1-6alkyl;

 \mathbf{R}^2 is hydrogen, $C_{1\text{-}6}$ alkyl, $C_{3\text{-}7}$ cycloalkyl, aryl, heteroaryl, aryl $C_{1\text{-}6}$ alkyl, heteroaryl $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl, hydroxy $C_{1\text{-}6}$ alkyl, aminocarbonyl, $C_{1\text{-}6}$ alkylaminocarbonyl, di($C_{1\text{-}6}$ alkyl)aminocarbonyl where each aryl or heteroaryl can be substituted one or more times by halogen, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkyl, hydroxy, amino, $C_{1\text{-}6}$ alkylamino, di($C_{1\text{-}6}$ alkyl)amino, amino $C_{1\text{-}6}$ alkyl, ($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, di($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, aryl or perhalo $C_{1\text{-}6}$ alkyl;

Q is a moiety of formula:

$$\mathbb{R}^5$$

wherein:

 $\mathbf{R^3}$ and $\mathbf{R^4}$ are each independently hydrogen, halogen, $C_{1\text{-}6}$ alkyl, perhalo $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkoxy, hydroxy, amino, $C_{1\text{-}6}$ alkylamino, di($C_{1\text{-}6}$ alkyl)amino, amino $C_{1\text{-}6}$ alkyl, ($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, di($C_{1\text{-}6}$ alkyl)amino $C_{1\text{-}6}$ alkyl, aryl;

R⁵ is hydrogen or C₁₋₆alkyl, and

R⁶ is hydrogen or hydroxymethyl,

in the manufacture of a medicament for administration to a human or animal patient for modulating the activity of the ORL-1 receptors.

22. (Original). Use according to claim 21, wherein said drug is useful in the prophylaxis and treatment of illnesses dependent on modulation of the ORL-1 receptor.